About Ubiquitin carboxyl-terminal hydrolase 34
Ubiquitin carboxyl-terminal hydrolase 34 (USP34) is a protein
from Homo sapiens identified by UniProt accession
Q70CQ2, 3546 residues long.
MolForge cross-references it against 0 known binders and
81 disease associations.
Target properties
| Protein name | Ubiquitin carboxyl-terminal hydrolase 34 |
|---|
| UniProt accession | Q70CQ2 |
|---|
| Gene | USP34 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 3546 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (81)
Diseases linked to this target (Open Targets).
- mean corpuscular volume · score 0.37
- chronotype measurement · score 0.35
- neutrophil count · score 0.35
- chromosome 2p16.1-p15 deletion syndrome · score 0.33
- reticulocyte count · score 0.33
- urate measurement · score 0.33
- leukocyte count · score 0.32
- sex hormone-binding globulin measurement · score 0.31
- FEV/FVC ratio · score 0.30
- mean reticulocyte volume · score 0.27
3D Structure (10)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Amino-acid sequence (3546 residues)
MCENCADLVE VLNEISDVEG GDGLQLRKEH TLKIFTYINS WTQRQCLCCF KEYKHLEIFN QVVCALINLV IAQVQVLRDQ LCKHCTTINI DSTWQDESNQ AEEPLNIDRE CNEGSTERQK SIEKKSNSTR ICNLTEEESS KSSDPFSLWS TDEKEKLLLC VAKIFQIQFP LYTAYKHNTH PTIEDISTQE SNILGAFCDM NDVEVPLHLL RYVCLFCGKN GLSLMKDCFE YGTPETLPFL IAHAFITVVS NIRIWLHIPA VMQHIIPFRT YVIRYLCKLS DQELRQSAAR NMADLMWSTV KEPLDTTLCF DKESLDLAFK YFMSPTLTMR LAGLSQITNQ LHTFNDVCNN ESLVSDTETS IAKELADWLI SNNVVEHIFG PNLHIEIIKQ CQVILNFLAA EGRLSTQHID CIWAAAQLKH CSRYIHDLFP SLIKNLDPVP LRHLLNLVSA LEPSVHTEQT LYLASMLIKA LWNNALAAKA QLSKQSSFAS LLNTNIPIGN KKEEEELRRT APSPWSPAAS PQSSDNSDTH QSGGSDIEMD EQLINRTKHV QQRLSDTEES MQGSSDETAN SGEDGSSGPG SSSGHSDGSS NEVNSSHASQ SAGSPGSEVQ SEDIADIEAL KEEDEDDDHG HNPPKSSCGT DLRNRKLESQ AGICLGDSQG MSERNGTSSG TGKDLVFNTE SLPSVDNRMR MLDACSHSED PEHDISGEMN ATHIAQGSQE SCITRTGDFL GETIGNELFN CRQFIGPQHH HHHHHHHHHH DGHMVDDMLS ADDVSCSSSQ VSAKSEKNMA DFDGEESGCE EELVQINSHA ELTSHLQQHL PNLASIYHEH LSQGPVVHKH QFNSNAVTDI NLDNVCKKGN TLLWDIVQDE DAVNLSEGLI NEAEKLLCSL VCWFTDRQIR MRFIEGCLEN LGNNRSVVIS LRLLPKLFGT FQQFGSSYDT HWITMWAEKE LNMMKLFFDN LVYYIQTVRE GRQKHALYSH SAEVQVRLQF LTCVFSTLGS PDHFRLSLEQ VDILWHCLVE DSECYDDALH WFLNQVRSKD QHAMGMETYK HLFLEKMPQL KPETISMTGL NLFQHLCNLA RLATSAYDGC SNSELCGMDQ FWGIALRAQS GDVSRAAIQY INSYYINGKT GLEKEQEFIS KCMESLMIAS SSLEQESHSS LMVIERGLLM LKTHLEAFRR RFAYHLRQWQ IEGTGISSHL KALSDKQSLP LRVVCQPAGL PDKMTIEMYP SDQVADLRAE VTHWYENLQK EQINQQAQLQ EFGQSNRKGE FPGGLMGPVR MISSGHELTT DYDEKALHEL GFKDMQMVFV SLGAPRRERK GEGVQLPASC LPPPQKDNIP MLLLLQEPHL TTLFDLLEML ASFKPPSGKV AVDDSESLRC EELHLHAENL SRRVWELLML LPTCPNMLMA FQNISDEQSN DGFNWKELLK IKSAHKLLYA LEIIEALGKP NRRIRRESTG SYSDLYPDSD DSSEDQVENS KNSWSCKFVA AGGLQQLLEI FNSGILEPKE QESWTVWQLD CLACLLKLIC QFAVDPSDLD LAYHDVFAWS GIAESHRKRT WPGKSRKAAG DHAKGLHIPR LTEVFLVLVQ GTSLIQRLMS VAYTYDNLAP RVLKAQSDHR SRHEVSHYSM WLLVSWAHCC SLVKSSLADS DHLQDWLKKL TLLIPETAVR HESCSGLYKL SLSGLDGGDS INRSFLLLAA STLLKFLPDA QALKPIRIDD YEEEPILKPG CKEYFWLLCK LVDNIHIKDA SQTTLLDLDA LARHLADCIR SREILDHQDG NVEDDGLTGL LRLATSVVKH KPPFKFSREG QEFLRDIFNL LFLLPSLKDR QQPKCKSHSS RAAAYDLLVE MVKGSVENYR LIHNWVMAQH MQSHAPYKWD YWPHEDVRAE CRFVGLTNLG ATCYLASTIQ QLYMIPEARQ AVFTAKYSED MKHKTTLLEL QKMFTYLMES ECKAYNPRPF CKTYTMDKQP LNTGEQKDMT EFFTDLITKI EEMSPELKNT VKSLFGGVIT NNVVSLDCEH VSQTAEEFYT VRCQVADMKN IYESLDEVTI KDTLEGDNMY TCSHCGKKVR AEKRACFKKL PRILSFNTMR YTFNMVTMMK EKVNTHFSFP LRLDMTPYTE DFLMGKSERK EGFKEVSDHS KDSESYEYDL IGVTVHTGTA DGGHYYSFIR DIVNPHAYKN NKWYLFNDAE VKPFDSAQLA SECFGGEMTT KTYDSVTDKF MDFSFEKTHS AYMLFYKRME PEEENGREYK FDVSSELLEW IWHDNMQFLQ DKNIFEHTYF GFMWQLCSCI PSTLPDPKAV SLMTAKLSTS FVLETFIHSK EKPTMLQWIE LLTKQFNNSQ AACEWFLDRM ADDDWWPMQI LIKCPNQIVR QMFQRLCIHV IQRLRPVHAH LYLQPGMEDG SDDMDTSVED IGGRSCVTRF VRTLLLIMEH GVKPHSKHLT EYFAFLYEFA KMGEEESQFL LSLQAISTMV HFYMGTKGPE NPQVEVLSEE EGEEEEEEED ILSLAEEKYR PAALEKMIAL VALLVEQSRS ERHLTLSQTD MAALTGGKGF PFLFQHIRDG INIRQTCNLI FSLCRYNNRL AEHIVSMLFT SIAKLTPEAA NPFFKLLTML MEFAGGPPGM PPFASYILQR IWEVIEYNPS QCLDWLAVQT PRNKLAHSWV LQNMENWVER FLLAHNYPRV RTSAAYLLVS LIPSNSFRQM FRSTRSLHIP TRDLPLSPDT TVVLHQVYNV LLGLLSRAKL YVDAAVHGTT KLVPYFSFMT YCLISKTEKL MFSTYFMDLW NLFQPKLSEP AIATNHNKQA LLSFWYNVCA DCPENIRLIV QNPVVTKNIA FNYILADHDD QDVVLFNRGM LPAYYGILRL CCEQSPAFTR QLASHQNIQW AFKNLTPHAS QYPGAVEELF NLMQLFIAQR PDMREEELED IKQFKKTTIS CYLRCLDGRS CWTTLISAFR ILLESDEDRL LVVFNRGLIL MTESFNTLHM MYHEATACHV TGDLVELLSI FLSVLKSTRP YLQRKDVKQA LIQWQERIEF AHKLLTLLNS YSPPELRNAC IDVLKELVLL SPHDFLHTLV PFLQHNHCTY HHSNIPMSLG PYFPCRENIK LIGGKSNIRP PRPELNMCLL PTMVETSKGK DDVYDRMLLD YFFSYHQFIH LLCRVAINCE KFTETLVKLS VLVAYEGLPL HLALFPKLWT ELCQTQSAMS KNCIKLLCED PVFAEYIKCI LMDERTFLNN NIVYTFMTHF LLKVQSQVFS EANCANLIST LITNLISQYQ NLQSDFSNRV EISKASASLN GDLRALALLL SVHTPKQLNP ALIPTLQELL SKCRTCLQQR NSLQEQEAKE RKTKDDEGAT PIKRRRVSSD EEHTVDSCIS DMKTETREVL TPTSTSDNET RDSSIIDPGT EQDLPSPENS SVKEYRMEVP SSFSEDMSNI RSQHAEEQSN NGRYDDCKEF KDLHCSKDST LAEEESEFPS TSISAVLSDL ADLRSCDGQA LPSQDPEVAL SLSCGHSRGL FSHMQQHDIL DTLCRTIEST IHVVTRISGK GNQAAS
Explore Ubiquitin carboxyl-terminal hydrolase 34 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets